Rhinosinusitis cost-effectiveness of therapy: Difference between revisions
Jump to navigation
Jump to search
| Line 5: | Line 5: | ||
==Cost-effectiveness of Therapy== | ==Cost-effectiveness of Therapy== | ||
Current literature suggests that in patients with refractory chronic rhinosinusitis endoscopic sinus surgery is superior to continued medical therapy in terms of symptom relief, quality of life and cost effectiveness | ===Medical therapy vs. Surgery=== | ||
Current literature suggests that in patients with refractory chronic rhinosinusitis endoscopic sinus surgery(ESS) is superior to continued medical therapy in terms of symptom relief, quality of life and cost effectiveness with reported incremental cost effectiveness ratio (ICER) of five to thirteen thousand dollars per quality adjusted life year (QALY). Medical therapy mostly helps maintain the quality of life and health-state utility of the patients.<ref name="pmid27863163">{{cite journal| author=Patel ZM, Thamboo A, Rudmik L, Nayak JV, Smith TL, Hwang PH| title=Surgical therapy vs continued medical therapy for medically refractory chronic rhinosinusitis: a systematic review and meta-analysis. | journal=Int Forum Allergy Rhinol | year= 2017 | volume= 7 | issue= 2 | pages= 119-127 | pmid=27863163 | doi=10.1002/alr.21872 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27863163 }} </ref><ref name="pmid31295554">{{cite journal| author=Codispoti CD, Mahdavinia M| title=A call for cost-effectiveness analysis for biologic therapies in chronic rhinosinusitis with nasal polyps. | journal=Ann Allergy Asthma Immunol | year= 2019 | volume= 123 | issue= 3 | pages= 232-239 | pmid=31295554 | doi=10.1016/j.anai.2019.07.004 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=31295554 }} </ref><ref name="pmid25186499">{{cite journal| author=Rudmik L, Soler ZM, Mace JC, Schlosser RJ, Smith TL| title=Economic evaluation of endoscopic sinus surgery versus continued medical therapy for refractory chronic rhinosinusitis. | journal=Laryngoscope | year= 2015 | volume= 125 | issue= 1 | pages= 25-32 | pmid=25186499 | doi=10.1002/lary.24916 | pmc=4280303 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25186499 }} </ref><ref name="pmid26991813">{{cite journal| author=Scangas GA, Su BM, Remenschneider AK, Shrime MG, Metson R| title=Cost utility analysis of endoscopic sinus surgery for chronic rhinosinusitis. | journal=Int Forum Allergy Rhinol | year= 2016 | volume= 6 | issue= 6 | pages= 582-9 | pmid=26991813 | doi=10.1002/alr.21697 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26991813 }} </ref> | |||
===Biologic therapies=== | |||
==References== | ==References== | ||
Revision as of 11:19, 5 December 2020
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Dima Nimri, M.D. [2]
Overview
Cost-effectiveness of Therapy
Medical therapy vs. Surgery
Current literature suggests that in patients with refractory chronic rhinosinusitis endoscopic sinus surgery(ESS) is superior to continued medical therapy in terms of symptom relief, quality of life and cost effectiveness with reported incremental cost effectiveness ratio (ICER) of five to thirteen thousand dollars per quality adjusted life year (QALY). Medical therapy mostly helps maintain the quality of life and health-state utility of the patients.[1][2][3][4]
Biologic therapies
References
- ↑ Patel ZM, Thamboo A, Rudmik L, Nayak JV, Smith TL, Hwang PH (2017). "Surgical therapy vs continued medical therapy for medically refractory chronic rhinosinusitis: a systematic review and meta-analysis". Int Forum Allergy Rhinol. 7 (2): 119–127. doi:10.1002/alr.21872. PMID 27863163.
- ↑ Codispoti CD, Mahdavinia M (2019). "A call for cost-effectiveness analysis for biologic therapies in chronic rhinosinusitis with nasal polyps". Ann Allergy Asthma Immunol. 123 (3): 232–239. doi:10.1016/j.anai.2019.07.004. PMID 31295554.
- ↑ Rudmik L, Soler ZM, Mace JC, Schlosser RJ, Smith TL (2015). "Economic evaluation of endoscopic sinus surgery versus continued medical therapy for refractory chronic rhinosinusitis". Laryngoscope. 125 (1): 25–32. doi:10.1002/lary.24916. PMC 4280303. PMID 25186499.
- ↑ Scangas GA, Su BM, Remenschneider AK, Shrime MG, Metson R (2016). "Cost utility analysis of endoscopic sinus surgery for chronic rhinosinusitis". Int Forum Allergy Rhinol. 6 (6): 582–9. doi:10.1002/alr.21697. PMID 26991813.